Top

Drugs

Published in:

01-12-2001 | Adis New Formulation Profile

Once-Weekly Fluoxetine

Authors: Antona J. Wagstaff, Karen L. Goa

Published in: Drugs | Issue 15/2001

Abstract

▴ The relatively long half-life of the selective serotonin reuptake inhibitor fluoxetine has allowed the development of a delayed-release (enteric-coated) formulation containing 90mg fluoxetine per capsule for once-weekly oral administration.
▴ The cumulative relapse rate in patients switched to once-weekly fluoxetine 90mg for 25 weeks (after responding to 13 weeks of fluoxetine 20 mg/day) was similar to that in patients continuing to receive fluoxetine 20 mg/day and significantly lower than seen in patients switched to placebo.
▴ The efficacy of the once-weekly formulation was also similar to that of the daily formulation in other assessment parameters (modified 17-item Hamilton Rating Scale for Depression, Clinical Global Impressions — Severity of Illness Scale).
▴ Patient compliance (measured using an electronically monitored tablet bottle) was maintained at 87.5% in evaluable patients receiving once-weekly fluoxetine 90mg for 12 weeks from a baseline of 85.4% after responding to 4 weeks of fluoxetine 20 mg/day; in contrast, compliance declined significantly (from 87.3% at baseline to 79.4%; p > 0.001) in patients continuing to receive 20 mg/day for 12 weeks.
▴ Once-weekly fluoxetine is well tolerated, with a tolerability profile similar to that of the immediate-release formulation.

Thase ME, Sullivan LR. Relapse and recurrence of depression: a practical approach for prevention. CNS Drugs 1995 Oct; 4: 261–77CrossRef

Donoghue J, Taylor DM. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 2000 May; 13: 365–83CrossRef

Schmidt ME, Fava M, Robinson JM, et al. The efficacy and safety of a new enteric-coated formulation of fluoxetine given once weekly during the continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Nov; 61(11): 851–7PubMedCrossRef

Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481–508PubMedCrossRef

Harris MG, Benfield P. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. Drugs Aging 1995; 6(1): 64–84PubMedCrossRef

Wilde MI, Benfield P. Fluoxetine: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 1998 May; 13 (5 Pt 1): 543–61PubMedCrossRef

Thase ME. Long-term nature of depression. J Clin Psychiatry 1999; 60 Suppl. 14: 3–9

Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 2000 Jul; 14(1): 51–80CrossRef

Simpson K, Noble S. Fluoxetine: areview of its use in women’s health. CNS Drugs 2000 Oct; 14(4): 301–28CrossRef

10.

Cheer SM, Goa KL. Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs 2001; 61(1): 81–110PubMedCrossRef

11.

Burke WJ, Hendricks SE, McArthur-Miller D, et al. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: results of a placebo-controlled, randomized clinical trial. J Clin Psychopharmacol 2000 Aug; 20: 423–7PubMedCrossRef

12.

Eli Lilly and Company. Prozac®: Fluoxetine hydrochloride product information. 2001 Feb 28 Indianapolis (IN): Eli Lilly and Company

13.

Eli Lilly and Company. Clinical Investigator’s Brochure: clinical studies — pharmacology. 1999 Dec 13 Indianapolis (IN): Eli Lilly and Company. (Data on file)

14.

Miner CM, Brown EB, Gonzales JS, et al. Switching patients from daily citalopram, paroxetine or sertraline to fluoxetine once-weekly in the maintenance of response for depression. 2001 Indianapolis (IN): Eli Lilly and Company. (Data on file)

15.

Schmidt ME, Michelson D, Judge R, et al. Long term treatment outcomes of depression with associated anxiety: efficacy of a new weekly formulation of fluoxetine (abstract no. P.03.178). Int J Neuropsychopharmacol 2000 Jul; 3 Suppl. 1: 228

16.

Claxton A, de Klerk E, Parry M, et al. Patient compliance to a new enteric-coated weekly formulation of fluoxetine during continuation treatment of major depressive disorder. J Clin Psychiatry 2000 Dec; 61(12): 928–32PubMedCrossRef

17.

Schmidt ME, Gonzales J, Michelson D. Sexual functioning during acute and continuation therapy with fluoxetine: a prospective assessment [abstract]. Psychosomatics 2001 Mar–2001 30; 42(2): 196

18.

Eli Lilly and Company. FDA approves Prozac Weekly as first and only medication administered weekly for long-term depression treatment. Media Rel 2001 Feb 27: 2

Title: Once-Weekly Fluoxetine
Authors: Antona J. Wagstaff
Karen L. Goa
Publication date: 01-12-2001
Publisher: Springer International Publishing
Published in: Drugs / Issue 15/2001
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200161150-00006

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Once-Weekly Fluoxetine

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 15/2001

Treatment Options in Hormone-Refractory Prostate Cancer

Renal Toxicity with Sevoflurane

Capecitabine

Once-Weekly Fluoxetine

Pharmacological Options for the Treatment of Tourette’s Disorder

Cetirizine/Pseudoephedrine